|
2024
|
P/S
|
Pharmaceutical preparations; pharmaceutical preparations for
use in urology. |
|
|
Invention
|
Method for discriminating interstitial cystitis. The present invention addresses the problem of p... |
|
2023
|
Invention
|
Pyrimidine derivative.
A compound represented by the following general formula (1), which has a ... |
|
|
Invention
|
Pyrimidine derivatives. Compounds represented by general formula (1), the compounds having strong... |
|
2022
|
Invention
|
Degrader.
To provide a novel compound that induces selective degradation of a non-receptor tyros... |
|
|
Invention
|
Degradation inducer. The present invention provides a novel compound that induces selective degra... |
|
|
Invention
|
Pyrimidine derivative.
A compound of the formula (I) or a salt thereof (R represents methyl grou... |
|
|
Invention
|
Pyrimidine derivative. The present invention pertains to: a compound that is represented by formu... |
|
2021
|
Invention
|
Powder preparation for nasal administration. A powder preparation for nasal administration contai... |
|
|
Invention
|
Solid preparation.
Provided is a solid preparation having an excellent stability and being usefu... |
|
|
Invention
|
Solid formulation. 1344 represents an alkylcarbonyl group such as an acetyl group, X represents a... |
|
|
Invention
|
Nicotinamide-encapsulating micelles, and pregnancy-induced hypertension syndrome therapy composit... |
|
|
Invention
|
A method of producing thyroid hormone-containing formulation. The present invention aims at impro... |
|
|
P/S
|
Chemicals; agricultural chemicals, except fungicides,
herbicides, insecticides and parasiticides... |
|
|
Invention
|
Methods for differentiating destructive thyroiditis from other pathological conditions.
Describe... |
|
|
Invention
|
Method for differentiating destructive thyroiditis from other pathological conditions. The presen... |
|
2020
|
Invention
|
Urination disorder-improving agent. 4 represents an alkylcarbonyl group such as acetyl group, X r... |
|
|
Invention
|
Dysuria-alleviating agent. 1344 represents an alkylcarbonyl group such as an acetyl group, X repr... |
|
2018
|
Invention
|
Powder preparation for nasal administration. The purpose of the present invention is to prepare a... |
|
|
Invention
|
Stable isotope-labeled compounds. Provided are a novel internal standard useful in the measuremen... |
|
|
Invention
|
Stable-isotope-labeled compound. Provided are: a novel internal standard substance that is useful... |
|
|
Invention
|
Pyrimidine derivative. A compound which has mPGES-1 inhibitory activity and is useful as an activ... |
|
|
Invention
|
15-oxosteroid compound and process for producing the same. Provided is a process for producing a ... |
|
|
Invention
|
15-oxosteroid compound and method for producing same. Provided is a method by which a compound, w... |
|
2017
|
Invention
|
Crystalline polymorph of 15b-hydroxy-osaterone acetate. Provided is a crystalline polymorphic for... |
|
|
Invention
|
Crystalline polymorph of 15β-hydroxy-osaterone acetate. Provided is a crystalline polymorph A of ... |
|
|
Invention
|
Medicinal drug containing fenofibrate. This formulation has excellent elutability and bioavailabi... |
|
2016
|
P/S
|
Chemical preparations for use in the manufacture of
pharmaceuticals; industrial chemicals; chemi... |
|
|
Invention
|
Pyrimidine derivative. 6 represents an alkyl group, or an alkoxy group), which has an mPGES-1 inh... |
|
|
Invention
|
Pyrimidine derivative. A compound represented by formula (1) or salt thereof which has an inhibit... |
|
|
P/S
|
Pharmaceutical preparations. |
|
2015
|
Invention
|
Microneedle device containing recombinant follicle stimulating hormone. The present invention pro... |
|
|
Invention
|
Mesenchymal stem cell and the method of use thereof. Demyelinated axons were remyelinated in the ... |
|
2014
|
Invention
|
Novel levonorgestrel crystal mixture and process for producing same. A levonorgestrel crystal mix... |
|
|
Invention
|
Substituted pyrrolo[1,2-a]quinoxalines as pde9 inhibitors. The invention discloses quinoxaline de... |
|
|
Invention
|
Amorphous levonorgestrel, solid dispersion, and manufacturing method for same. Provided are a ne... |
|
|
Invention
|
Β crystalline polymorph of levonorgestrel, and manufacturing method for same. Provided are a new... |
|
|
Invention
|
Α crystalline polymorph of levonorgestrel, and manufacturing method for same. Provided are a new... |
|
|
Invention
|
Crystal of 2-(3,4-dichlorobenzyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxylic ... |
|
2013
|
Invention
|
Crystalline polymorphic form of ulipristal acetate. A novel crystalline polymorphic form of ulipr... |
|
|
Invention
|
Amorphous ulipristal acetate. A novel form of ulipristal acetate useful as an agent for preventin... |
|
2012
|
Invention
|
Substituted imidazo[1,5-a]quinoxalines as phosphodiesterase 9 inhibitors. The invention discloses... |
|
|
Invention
|
Thienopyrimidine derivatives. This invention provides thienopyrimidine derivatives of the formula... |
|
|
Invention
|
Mesenchymal stem cell and a method of use thereof. Demyelinated axons were remyelinated in the de... |
|
|
P/S
|
Pharmaceutical or medical products for human use;
biotechnological products for medical purposes... |
|
2011
|
Invention
|
Kip1 degradation inhibitor. Kip1 is provided. The compound or the salt thereof is represented by ... |
|
|
Invention
|
Crystal of 2-(3,4 dichlorobenzyl)-5-methyl-4-oxo-3,4-dihydrothien[2,3-d]pyrimidine-6-carboxylic a... |
|
|
Invention
|
Heterocyclic compound and h1 receptor antagonist. A heterocyclic compound useful as an antiallerg... |
|
|
Invention
|
Solid preparation.
The present invention relates to a solid preparation having an easily control... |
|
2009
|
P/S
|
Pharmaceutical or medical products for human use;
biotechnological products for medical use, for... |
